Regarding TG Therapeutics, ClearBridge Small Cap Growth Strategy stated the following in its Q4 2024 investor letter: “TG Therapeutics is a commercial-stage biotechnology company focused on ...

Following numerous positive meetings last year, 2025 will be all about follow up and cementing partnerships for Scandium ...

Group reveals significant uptick in early winter revenue and earnings, although seasonal losses in its northern Europe region ...

For Howden’s London operation, the risks are very clear. The channel conflict presented by owning a US retailer – a direct ...

TD Cowen analyst Tara Bancroft maintained a Buy rating on TG Therapeutics (TGTX – Research ... indicating confidence in the company’s future growth prospects. In another report released ...

As global markets navigate a landscape of tariff uncertainties and mixed economic signals, with the S&P 500 Index showing resilience despite recent declines, investors are closely monitoring how these ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

The United States market has shown a steady performance with no significant change over the last week, but it is up 22% over ...

MaxCyte ( NASDAQ: MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...